Literature DB >> 14999772

Expression mapping at 12p12-13 in advanced prostate carcinoma.

Adam S Kibel1, John Huagen, Chan Guo, William B Isaacs, Yan Yan, Kenneth J Pienta, Paul J Goodfellow.   

Abstract

We have previously mapped a putative prostate cancer tumor-suppressor gene to a 1-2 Mb region of 12p12-13. Initial work to identify the tumor suppressor at this locus focused on candidates previously implicated in malignancy; however, mutational and methylation analyses failed to identify significant genomic events. An alternative approach is to use expression analysis to prioritize the genes within the region of interest. This experimental design is based on the hypothesis that tumor-suppressor genes demonstrate decreased expression in tumors compared to normals. Herein, we narrow the region of interest using deletion mapping data and employ expression analysis to prioritize the genes in the minimal deleted region. Highly informative polymorphic markers spanning our region were used to assess for loss of heterozygosity in 99 tumor and normal DNA pairs. The minimal region of deletion was determined to be approximately 500 kb bounded by D12S391 and A002Q26. Publically available databases place 7 genes within this minimal deletion region. An additional 3 genes lie just outside this minimal deletion region and could possibly be inactivated by deletion of promoter, 3'-untranslated region sequences or alternative splice variants. Relative levels of expression of these 10 candidate genes were determined in 6 normal prostates, 5 local prostate tumors, 9 prostate lymph node metastases, 6 prostate cancer cell lines and 12 prostate cancer xenografts using quantitative RT-PCR. DUSP16, FLJ10298 and BCLG were significantly downregulated in both clinical tumors and cultured prostate cancer tissue, indicating that one or all may be critical to initiation or progression of prostate carcinoma. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999772     DOI: 10.1002/ijc.20060

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.

Authors:  A M Luebke; T Schlomm; B Gunawan; H Bonkhoff; L Füzesi; A Erbersdobler
Journal:  Virchows Arch       Date:  2005-02-22       Impact factor: 4.064

Review 2.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

3.  Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma.

Authors:  B H Morrison; R Haney; E Lamarre; J Drazba; G D Prestwich; D J Lindner
Journal:  Oncogene       Date:  2009-05-11       Impact factor: 9.867

4.  DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma.

Authors:  S Lee; N Syed; J Taylor; P Smith; B Griffin; M Baens; M Bai; K Bourantas; J Stebbing; K Naresh; M Nelson; M Tuthill; M Bower; E Hatzimichael; T Crook
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

Review 5.  Regulatory Roles of MAPK Phosphatases in Cancer.

Authors:  Heng Boon Low; Yongliang Zhang
Journal:  Immune Netw       Date:  2016-04-28       Impact factor: 6.303

6.  DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.

Authors:  Heng Boon Low; Zhen Lim Wong; Bangyuan Wu; Li Ren Kong; Chin Wen Png; Yik-Lam Cho; Chun-Wei Li; Fengchun Xiao; Xuan Xin; Henry Yang; Jia Min Loo; Fiona Yi Xin Lee; Iain Bee Huat Tan; Ramanuj DasGupta; Han-Ming Shen; Herbert Schwarz; Nicholas R J Gascoigne; Boon Cher Goh; Xiaohong Xu; Yongliang Zhang
Journal:  Nat Commun       Date:  2021-04-16       Impact factor: 14.919

7.  Detection of Bcl-2 family member Bcl-G in mouse tissues using new monoclonal antibodies.

Authors:  M Giam; J D Mintern; G J P Rautureau; M G Hinds; A Strasser; P Bouillet
Journal:  Cell Death Dis       Date:  2012-08-23       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.